Subscribe: PHYSorg.com: Cancer News
http://www.physorg.com/rss-feed/health-news/cancer/
Added By: Feedage Forager Feedage Grade A rated
Language: English
Tags:
breast cancer  breast  cancer cells  cancer  cell  cells  medicine  new  patients  researchers  study  treatment  tumor  university 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: PHYSorg.com: Cancer News

Cancer News - Health News, Medicine News, Cancer



Phys.org provides the latest news on cancer, health, medicines, cancer treatments, cancer research, cancer studies and types of cancer.



 



Molecular dissection of bile duct cancer reveals subtypes with different origins and varying potential treatments

Wed, 13 Dec 2017 07:46:44 EST

Researchers have discovered that cholangiocarcinoma (CCA), a form of liver cancer also known as bile duct cancer, consists of several molecular subtypes with distinct potential therapies and prognoses.



Closing in on advanced prostate cancer

Wed, 13 Dec 2017 06:46:12 EST

In most cases, prostate cancer is cured by surgery and/or radiotherapy. However, 20 percent of patients will need treatment to remove tumour cells but this treatment ceases to be effective after two or three years and the cancer recurs. Once this stage of the disease is reached, there is no cure. A team headed by Xavier Salvatella, ICREA researcher at the Institute for Research in Biomedicine (IRB Barcelona), has discovered a new avenue through which to attack prostrate cancer cells that have developed drug resistance. Published in the journal Structure, the study opens up new therapeutic avenues against a disease that causes 75,000 deaths a year in Europe alone.



New discovery may enhance chemotherapy's efficiency against leukaemia

Wed, 13 Dec 2017 06:24:39 EST

In patients with acute myeloid leukaemia, cancer cells resist the effects of chemotherapy, many times resulting in disease recurrence and ultimately death. Researchers from Instituto de Medicina Molecular (iMM) João Lobo Antunes have found a mechanism through which certain types of leukaemia resist chemotherapy, thus revealing novel molecular targets that may be used to improve the efficiency of this type of treatment.



Allopurinol Rx more likely with eligibility at diagnosis

Tue, 12 Dec 2017 17:00:01 EST

(HealthDay)—Allopurinol prescribing is more likely if patients meet eligibility criteria at diagnosis, according to a research brief published in the November/December issue of the Annals of Family Medicine.



Skin cancer treatment selfie goes viral, has public health lessons

Tue, 12 Dec 2017 15:46:40 EST

You've heard of the Katie Couric effect, the Angelina Jolie effect and the Charlie Sheen effect, but could the next effect be named after you?



Atoh1, a potential Achilles' heel of Sonic Hedgehog medulloblastoma

Tue, 12 Dec 2017 14:44:48 EST

Medulloblastoma is the most common type of solid brain tumor in children. Current treatments offer limited success and may leave patients with severe neurological side effects, including psychiatric disorders, growth retardation and cognitive impairment.



Researchers develop test that can diagnose two cancer types

Tue, 12 Dec 2017 14:33:02 EST

A blood test using infrared spectroscopy can be used to diagnose two types of cancer, lymphoma and melanoma, according to a study led by Georgia State University.



Cancer-causing mutation suppresses immune system around tumours

Tue, 12 Dec 2017 14:32:06 EST

Mutations in 'Ras' genes, which drive 25% of human cancers by causing tumour cells to grow, multiply and spread, can also protect cancer cells from the immune system, finds a new study from the Francis Crick Institute and Institute of Cancer Research (ICR), London.



A gold-standard cancer treatment is in decline, and money may be why

Tue, 12 Dec 2017 10:53:02 EST

The evidence is clear: Cervical cancer is best treated with brachytherapy, a form of radiation therapy. Yet the use of this potentially lifesaving treatment has been declining, and a new study from the University of Virginia School of Medicine may explain why.



Transfusion dependence a barrier to quality end-of-life care for some with leukemia

Tue, 12 Dec 2017 03:39:12 EST

For patients with advanced leukemia, access to high-quality end-of-life care appears to be reduced in those dependent on blood transfusions, according to a new study being presented during the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta. The study associates this reduced access and consequent diminished use of hospice services with a reduced quality of end-of-life care for these patients.



People aged 75 years and older are underrepresented in blood cancer clinical trials

Tue, 12 Dec 2017 03:37:02 EST

In the first comprehensive analysis of clinical trial enrollment among older adults with blood cancers, researchers from the U.S. Food and Drug Administration (FDA) found significant gaps in participation among those aged 75 and older when considered against the incidence of these malignancies in this age group, according to research being presented today during the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta. By comparison, adults under 65 years tend to be overly represented in these trials, despite the fact that a majority of blood cancers are most frequently diagnosed in those over 65 years of age.



Drug suppresses spread of breast cancer caused by stem-like cells

Tue, 12 Dec 2017 03:36:25 EST

Rare stem-like tumor cells play a critical role in the spread of breast cancer, but a vulnerability in the pathway that powers them offers a strategy to target these cells using existing drugs before metastatic disease occurs, report University of California San Diego School of Medicine and Moores Cancer Center researchers.



MRI scans predict patients' ability to fight the spread of cancer

Tue, 12 Dec 2017 03:29:48 EST

A simple, non-invasive procedure that can indicate how long patients with cancer that has spread to the brain might survive and whether they are likely to respond to immunotherapy has been developed by researchers in Liverpool.



Increasing physical activity improves survival in lymphoma patients, researchers say

Mon, 11 Dec 2017 19:50:01 EST

An observational study by researchers at Mayo Clinic has found that increasing physical activity not only decreased the risk of death from all causes but also decreased the risk of death specifically from lymphoma. Lymphoma is a cancer of the lymphatic system, the part of the body's germ-fighting network which includes the lymph nodes (lymph glands), spleen, thymus gland and bone marrow. Lymphoma can affect those areas as well as other organs throughout the body. Study results were presented today at the 59th American Society of Hematology annual meeting in Atlanta by Priyanka Pophali, M.B.B.S., a hematologist at Mayo Clinic.



Insights on how SHARPIN promotes cancer progression

Mon, 11 Dec 2017 16:31:47 EST

Researchers at Sanford Burnham Prebys Medical Discovery (SBP) and the Technion in Israel have found a new role for the SHARPIN protein. In addition to being one of three proteins in the linear ubiquitin chain assembly complex (LUBAC), regulating NFκB and other inflammatory molecules, SHARPIN modulates PRMT5, an epigenetic master switch that controls several proteins linked to melanoma. The research was published in The Journal of Clinical Investigation.



PUMA pathway is a weak link in breast cancer metastasis

Mon, 11 Dec 2017 16:00:01 EST

Substantial advancements have improved the success of chemotherapy, radiation, and surgical treatments for primary breast cancers. However, breast cancer that has spread, or metastasized, to other parts of the body remains a challenge to cure. It is difficult to predict whether a tumor will recur and metastasize, and uncertainty can lead to inadequate or overaggressive treatment.



Glioblastoma survival mechanism reveals new therapeutic target

Mon, 11 Dec 2017 15:52:15 EST

A Northwestern Medicine study, published in the journal Cancer Cell, has provided new insights into a mechanism of tumor survival in glioblastoma and demonstrated that inhibiting the process could enhance the effects of radiation therapy.



ASH: Anti-CD19 CAR T-cell Tx beneficial in B-cell lymphomas

Mon, 11 Dec 2017 13:50:01 EST

(HealthDay)—Axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy and autologous T cells that express a CD19-directed CAR (CTL019) are effective for refractory B-cell lymphomas, according to two studies published online Dec. 10 in the New England Journal of Medicine to coincide with the annual meeting of the American Society of Hematology, held from Dec. 9 to 12 in Atlanta.



ASH: A+AVD beats ABVD for advanced Hodgkin's lymphoma

Mon, 11 Dec 2017 13:40:02 EST

(HealthDay)—For patients with advanced-stage Hodgkin's lymphoma, brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) have superior efficacy to doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), according to a study published online Dec. 10 in the New England Journal of Medicine to coincide with the annual meeting of the American Society of Hematology, held from Dec. 9 to 12 in Atlanta.



Scientists discover possible master switch for programming cancer immunotherapy

Mon, 11 Dec 2017 13:04:54 EST

During infection or tumor growth, a type of specialized white blood cells called CD8+ T cells rapidly multiply within the spleen and lymph nodes and acquire the ability to kill diseased cells. Some of these killer T cells then migrate where required to vanquish the germs or cancers.



Report: New system for more accurate cancer staging to aid precision medicine

Mon, 11 Dec 2017 12:56:36 EST

Adding a blood test called liquid biopsy to a standard tissue biopsy could significantly improve the accuracy of diagnosis and treatment for patients with cancer, according to researchers at Wake Forest Baptist Medical Center.



AML study reports high response rates with combination targeted therapy

Mon, 11 Dec 2017 12:00:04 EST

Initial findings from a multi-national open-label phase Ib study of inhibitory drug therapy for relapsed or refractory acute myeloid leukemia (AML) have demonstrated a complete response in up to 50 percent patients say researchers at The University of Texas MD Anderson Cancer Center .



Liver cancer: Lipid synthesis promotes tumor formation

Mon, 11 Dec 2017 12:00:03 EST

Lipids comprise an optimal energy source and an important cell component. Researchers from the Biozentrum of the University of Basel and from the University of Geneva have now discovered that the protein mTOR stimulates the production of lipids in liver tumors to satisfy the increased nutrient turnover and energy needs of cancer cells, among other functions. This process has also been observed in patients with liver cancer as the scientists report in Cancer Cell.



A new weapon against bone metastasis? Team develops antibody to fight cancer

Mon, 11 Dec 2017 12:00:01 EST

In the ongoing battle between cancer and modern medicine, some therapeutic agents, while effective, can bring undesirable or even dangerous side effects. "Chemo saves lives and improves survival, but it could work much better if you eliminate unwanted side effects from it," said Princeton University cancer researcher Yibin Kang, the Warner-Lambert/Parke-Davis Professor of Molecular Biology.



Using software, researchers predict tumor markers that could be immune targets

Mon, 11 Dec 2017 11:47:32 EST

University of North Carolina Lineberger Comprehensive Cancer Center scientists have developed a software program that can accurately predict which tumor-specific markers will show up on the surface of leukemia cells in patients who have received stem cell transplants. Researchers plan to use their findings to develop immune-based therapies that target these antigens in leukemia patients.



Pushing the boundaries of melanoma border detection

Mon, 11 Dec 2017 11:36:31 EST

Skin cancer experts will soon be able to benefit from a better way of spotting and identifying lesions, thanks to an improved image segmentation tool developed by computer scientists at Brunel University London.



Use of chemotherapy for early stage breast cancer declines, study says

Mon, 11 Dec 2017 09:32:12 EST

A study of nearly 3,000 women with early stage breast cancer indicates a recent, significant decline in the use of chemotherapy despite the lack of any change in national treatment recommendations or guidelines, according to researchers at the Stanford University School of Medicine and the University of Michigan.



Immunotherapy strategy could be beneficial for relapsed acute myeloid leukemia

Mon, 11 Dec 2017 09:31:40 EST

University of North Carolina Lineberger Comprehensive Cancer Center researchers report that pairing an immunotherapy drug with chemotherapy proved beneficial for some patients with acute myeloid leukemia whose disease did not respond to standard treatment or had relapsed.



Researchers identify epigenetic orchestrator of pancreatic cancer cells

Mon, 11 Dec 2017 09:00:01 EST

Genentech researchers have identified an enzyme that shifts pancreatic cancer cells to a more aggressive, drug-resistant state by epigenetically modifying the cells' chromatin. The study, which will be published December 11 in the Journal of Cell Biology, suggests that targeting this enzyme could make pancreatic cancer cells more vulnerable to existing therapies that currently have only limited effect against this deadly form of cancer.



Drinking and the risk of cancer

Mon, 11 Dec 2017 07:47:04 EST

It's no secret that drinking alcohol is a risk factor for cancer. The National Cancer Institute says alcohol use is associated with a higher risk of developing cancers of the head and neck, esophagus, liver, breast, colon and rectum.